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Purpose: Accurate estimates of disease incidence in children are required to support pediatric
drug development. Analysis of electronic health care records (EHR) may yield such estimates but
pediatric‐specific methods are lacking. We aimed to understand the impact of assumptions
regarding duration of disease episode and length of run‐in period on incidence estimates from
EHRs.
Methods: Children aged 0 to 17 years (5–17 years for asthma) registered in the Integrated
Primary Care Information database between 2002 and 2014 were studied. We tested the impact
of the following: maximum duration of disease episode (0, 14, 30, 60, and 90 days) on recurrent
diseases (acute otitis media [common] and acute pyelonephritis [rare]); and database run‐in
period on chronic diseases—asthma (common) and type 1 diabetes (DM) (rare). We calculated
incidence rate ratios with 95% confidence intervals and stratified using 1‐year age categories.
Results: Altogether, 503 495 children were registered. The incidence of acute otitis media
was highest in <2‐year‐old children; using 30 days disease duration as reference, the rate
increased with 8% if the duration was 14 days and decreased with 8% when extended to 60 days.
Disease duration did not impact acute pyelonephritis (rare). No run‐in (to exclude prevalent cases)
versus 24‐month run‐in period overestimated the incidence rate for asthma and DM by a factor
of 2.
Conclusions: Analysis of EHR allows for estimation of disease incidence in children, but
assumptions regarding episode length and run‐in period impact the incidence estimates. Such
assumptions may be routinely explored.
KEYWORDS
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Globally, legislations have been introduced to stimulate development
of drugs for children specifically.1-3 Regulatory authorities now require- - - - - - - - - - - - - - - - - - - - - - - - - - -
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adapharmaceutical companies to include pediatric investigation plans
(PIPs) when submitting proposals for drug development in adults. PIPs
may be waived if the target indication affects only adults. For PIPs that
are considered for approval, the potential therapeutic benefits for chil-
dren should be explained in the document. Such explanation may
include data regarding the background occurrence of the indication
in the pediatric population.4- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
y & Sons Ltd.
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KEY POINTS
• Limitations arising from lack of standardized
methodologies to calculate incidence of disease in
children may lead to heterogeneity in reported incidence
data that are required for the pediatric investigation plans.
• As part of the Global Research in Pediatrics, we
demonstrate the impact of applying different assumptions
regarding duration of disease episode and run‐in period
and provide recommendations for dealing with these.
2 OSOKOGU ET AL.Population‐based electronic health care records (EHR) provide an
excellent data source for estimation of disease occurrence;5 however, there
are specific methodological challenges that should be considered based on
the fact that these data are not collected for research but for every day care.
First, since EHR was introduced only in the last few decades, soft-
ware systems may change, and patients may move between physi-
cians/health care plans. Therefore, the data often capture only a
specific (limited) part of an individual's life‐time. In order to distinguish
incident from prevalent disease, researchers usually apply a look‐back
(run‐in) period which is often arbitrarily chosen and the impact of the
choice is not investigated or reported.6 In addition, patients (or their
parents) visit a physician usually at the start of a disease but not
anymore once the disease has resolved, which hampers calculation of
the duration of transient diseases.
Secondly, the characteristics of childhood diseases present addi-
tional challenges; children suffer from mostly common transient infec-
tion‐related disease such as acute otitis media (AOM). On the other
end of the spectrum of recurrent diseases, there may be rare diseases
like acute pyelonephritis (APN).7,8 Diseases that affect children may
also be chronic and differ in frequency: asthma is common and chronic
unlike type 1 diabetes (DM) which is also chronic but less common.9,10
It would be important to understand the impact of different assump-
tions on estimates of disease occurrence.
As part of the Global Research in Pediatrics—Network of Excel-
lence (http://www.grip‐network.org/), we aimed to understand how
different assumptions regarding duration of a disease episode (for
transient and recurrent diseases) and run‐in period (for chronic dis-
eases) may impact incidence and prevalence estimates. As examples,
we investigated AOM and APN (both transient and recurrent), and
asthma and type 1 diabetes (both chronic conditions).2 | METHODS
2.1 | Setting
This retrospective cohort study was performed using the Integrated
Primary Care Information (IPCI) database as an example for other
electronic health care databases. IPCI is a longitudinal, observational,
primary care database with records of approximately 1 500 000
patients from approximately 450 general practitioners (GPs) in the
Netherlands. The records comprise information on patient demo-
graphics, symptoms and diagnoses, referrals, laboratory tests and
results, drug prescriptions, hospitalizations, and discharge letters.
Details of the data source have been published elsewhere.11 Diagno-
ses are coded according to the International Classification for Primary
Care (ICPC).12 Drug names are coded following the World Health
Organization‐Anatomic Therapeutic Chemical (WHO‐ATC) classifica-
tion system. The database has been proven to be valid for conducting
pharmacoepidemiological studies.132.2 | Study population
All children aged 0 to 17 years that were registered for at least 1 day
between January 1, 2002 and December 31, 2014 could be included
in the study. For the investigation of asthma, the minimum age forinclusion was 5 years because the diagnosis of asthma in children under
5 years old is prone to misclassification due to the high incidence of viral
infections associated with wheezing.14,15 Patients entered the study
population at the latest of the following dates: start of the study period,
date of birth or date of registration in IPCI, age of 5 years (asthma only).
For both asthma and type 1 diabetes, patients needed to have up to
24 months' run‐in to be included in the study population.
Exit from the study population occurred at the earliest of the
following events: leaving the GP practice, death, subject turned
18 years old, or end of the study period.2.3 | Outcome definition and identification
Four outcomes of interest were studied based on different durations
(transient or chronic) and frequencies (common or rare). The outcomes
were identified based on diagnosis and prescription codes. See
appendix 1.
Acute otitis media (AOM) is a transient disease, the systemic and local
features of AOM usually resolve within 24 to 72 hours.16,17 One patient
can experience more than 1 episode of AOM.18 Children with AOMwere
identified through a search on the ICPC AOM disease code H74.
Acute pyelonephritis (APN) is also a transient disease. In the
Netherlands, ICPC disease code U70 implies that APN was diagnosed
by urine testing.19 Also, this code distinguishes APN from cystitis which
is assigned the ICPC disease code U71 thereby preventing misclassifica-
tion of both forms of urinary tract infection (UTI). APNmay be recurrent.20
Asthma is a chronic and rather common condition in children.10
Cases were identified by combining the ICPC disease code (R96) with
at least 2 prescriptions for asthma medication (ATC code R03) in the
year following the initial diagnosis.10,21
Type 1 diabetes (DM) is a chronic and rare disease in children. Cases
were identified by combining ICPCdisease code (T90) and at least 1 pre-
scription for insulin (A10A) in the year following the initial diagnosis.222.4 | Statistical analyses
Overall and age‐specific incidence rates (IR) were calculated by
dividing the events/outcomes by the total number of person‐years
(PY) accumulated in the study population. The IR was expressed per
100 000 PY. Age stratification was done in 1‐year categories. For the
transient outcomes (AOM and APN), recurrent episodes were consid-
ered as new events based on a duration of episode of 0, 14, 30, 60,
OSOKOGU ET AL. 3and 90 days. Person‐time was not censored at diagnosis. For the
chronic outcomes, person‐time was censored at the date of first
diagnosis. The run‐in period was reduced from 24 to 12 and 6 months
to assess the impact on the incidence rate. Further, the impact of not
applying a run‐in period was tested. The 95% confidence intervals
(CI) around the incidence rates were estimated based on the negative
binomial distribution.23 For the transient outcomes (AOM and APN),
age‐specific incidence rate ratios (IRR) were calculated by comparing
the IRs based on clinically plausible episode durations—14 days vs
30 days. For the chronic outcomes (asthma and DM), age‐specific IRRs
were calculated by dividing the IR resulting from not applying run‐in vs
24 months' run‐in.
As presented in Figure 1, point prevalence was calculated on July
1, 2010 by dividing the number of children with the outcome on that
date by the total number of children in the study population on that
date. 95% CIs were calculated based on the Wilson score interval.24
To calculate the age‐specific prevalence ratio (PR) for the transient
outcomes (AOM and APN), we assumed an event to be new if it
occurred ≥30 days after the preceding event, and we divided the
resulting point prevalence by the estimate that was based on 14 days'
episode duration. Regarding the chronic outcomes (asthma and DM),
age‐specific PRs were calculated by dividing the point prevalence
resulting from 24 months' run‐in vs no run‐in. For the calculation of
the point prevalence based on the 24 months' run‐in, this meant that
only those children with a database history of at least 24 months could
be included in the denominator. Of these children, only those that met
the case definition (as described earlier) prior to July 1, 2010 were
included in the numerator. No run‐in meant that no database history
was required for inclusion. The 95% CIs around the IRRs and PRRs
were calculated following the negative binomial distribution.25
Analyses were conducted using a custom‐built Java application
called Jerboa Reloaded (Erasmus University Medical Center,
Rotterdam), and IBM SPSS Statistics for windows version 21.0,
Armonk, NY: IBM Corp.FIGURE 1 Study schematic showing the run‐in periods, start of follow‐u
wileyonlinelibrary.com]3 | RESULTS
To investigate AOM and APN, the study population comprised
503 495 children. For asthma (studied in children 5 years or older)
and DM, we studied 304 856 and 405 600 children, respectively; the
total PYs of follow‐up were 710 980 PY and 1 042 067 PY. Figure 2
shows the distribution of age (at start of follow‐up [no run in]) and
duration of follow‐up of the population base, without censoring.Recurrent diseases and impact of episode duration
Based on the assumptions that a new event can only re‐occur 0,≥14,≥30,
≥60, or≥90 days after the preceding event, overall IRs for AOMdecreased
from 8.2, 7.1, 6.6, 6.2 to 5.9 per 100 PY, respectively (Table 1).
The estimates resulting from the shortest assumed duration were
the highest, decreasing with increasing length of an episode in all age
categories (Figure 3).
Incidence was highest in the youngest children although this did not
affect the impact of episode duration on the IRR: comparing 14 vs
30 days: IRR = 1.10 (95% CI: 1.08; 1.12) for subjects aged <1 year and
1.09 (95% CI: 1.07; 1.11) for subjects aged 1–2 years; overall IRR = 1.08
(95% CI: 1.07; 1.09). The IRs for APN were much lower than for AOM.
Assuming 0,≥14, ≥30, ≥60, or ≥90 days between new events, the over-
all IRs reduced relatively little from 31.1, 29.6, 28.9, 27.9 to 27.0 per
100 000 PY, respectively. The age‐specific IRRs to test assumptions on
duration of episodes comparing 14 vs 30 days were all around 1, showing
no age specific effect modification of the impact of episode duration.
The impact of episode duration length had quite an opposite
effect on the point prevalence: with increasing duration of episodes,
the point prevalence increased. The overall PRR that compared an
episode duration of 30 days to 14 days' duration for AOM was 1.92
(95% CI: 1.73; 2.12), which was higher than for APN: 1.50 (95% CI:
0.25; 8.98). In APN, the impact was less pronounced due to a very
low prevalence overall.p and timing of outcome definitions [Colour figure can be viewed at
FIGURE 2 Median follow‐up time according
to the age categories of the studied
populations [Colour figure can be viewed at
wileyonlinelibrary.com]
4 OSOKOGU ET AL.Chronic diseases and impact of run‐in/naïve period
By applying a 0, 6, 12, or 24 months' naïve period, overall IRs for
asthma (age 5–17 years) lowered from 5.96, 4.76, 3.92 to 2.65 per
1000 PY, respectively. The impact of a 0 vs 24 months' run‐in was a
more than 2‐fold increase in IR across all ages (Figure 4), IRR over-
all = 2.25 (95%CI: 2.13; 2.38).
By applying a 0, 6, 12, or 24 months' naïve period, overall IRs for
DMwere 2.46, 2.03, 1.65, and 1.10 per 10 000 PY, respectively. Again,
the highest IRs were observed when no run‐in was applied and the IRs
were lowest with 24‐months' run‐in. The impact of applying 0 vs24 months' run‐in leads to a 2‐fold increase in incidence rate in most
age categories, IRR overall = 2.22 (95%CI: 1.79; 2.77). The impact of
an increase in the run‐in period, during which prevalent cases would
be identified and excluded, was a lowering of the rate of asthma as well
as DM.
The impact of applying a 24 months' run‐in vs no run‐in on the
age specific point prevalence was negligible for both asthma (overall
PRR: 1.10 [95% CI: 1.06; 1.14]) as well as DM (overall PRR: 0.82
[95% CI: 0.64; 1.04]).
The results are summarized in Figure 5.
TABLE 1 Total number of studied children, total person‐years (PY) of follow‐up, total number of incident events (transient and recurrent out-
comes) or cases (chronic outcomes) and overall incidence rates according to the investigated outcomes
Outcome Assumption a
Total Number




(per 100 000 PY)
Acute otitis media 0 days 503 495 1 781 625 146 391 8216.7
≥14 days 503 495 1 761 172 124 749 7083.3
≥30 days 503 495 1 752 235 115 107 6564.0
≥60 days 503 495 1 746 245 107 860 6176.7
≥90 days 503 495 1 742 821 103 089 5915.1
Acute pyelonephritis 0 days 503 495 1 734 774 540 31.1
≥14 days 503 495 1 734 750 513 29.6
≥30 days 503 495 1 734 740 502 28.9
≥60 days 503 495 1 734 724 484 27.9
≥90 days 503 495 1 734 713 468 27.0
Asthmab No run‐in 304 856 710 980 4238 596.1
6‐month run‐in 304 856 710 980 3385 476.1
12‐month run‐in 304 856 710 980 2786 391.9
24‐month run‐in 304 856 710 980 1881 264.6
Type 1 diabetes No run‐in 405 600 1 042 067 256 24.6
6‐month run‐in 405 600 1 042 067 212 20.3
12‐month run‐in 405 600 1 042 067 172 16.5
24‐month run‐in 405 600 1 042 067 115 11.0
aFor the transient outcomes, this refers to the time between new episodes; for the chronic outcomes, it refers to the length of the run‐in period.
bFor asthma and type 1 diabetes, subjects that had a minimum 24‐month run‐in were studied to know the impact of decreasing the run‐in period on the
incidence rate
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This study showed that assumptions regarding duration of a dis-
ease episode (for transient and recurrent diseases) and run‐in
period (for chronic diseases) may impact incidence and prevalence
estimates of childhood diseases obtained from population‐based
dynamic EHR databases. While this study was focused on children,
some of the investigated issues may also be relevant for adults.
The lack of complete follow‐up from birth till 17 years of age,
and the fact that only the visit for a disease and not the ending
of a disease is recorded in the electronic medical record has an
impact on estimation of disease occurrence. Usually, epidemiolo-
gists apply assumptions to deal with these limitations, such as
“assuming a standard disease episode duration” and use of a run‐
in period prior to start of follow‐up that can be used to exclude
prevalent disease. In this paper, we wanted to investigate the
impact of these assumptions on the different occurrence measures
in children, and we witnessed relatively great impact. General rules
can be obtained from this exercise: for common recurrent diseases,
the impact of the choice of episode duration is relatively high,
assuming longer disease episodes leads to lower incidence. The
impact of a change in episode duration on the incidence is negligi-
ble in a rare recurrent disease. This is understandable because the
probability of having another event of a rare disease is low, and
this will not likely occur close together. The impact of an increasing
episode duration on the prevalence of a common recurrent disease
is opposite, with increasing duration the point prevalence
increases. The impact is negligible on the point prevalence for a
rare recurrent disease. We recommend that studies aiming to esti-
mate incidence and prevalence of common recurrent diseases bet-
ter explore the impact of the episode length because the true
length cannot be observed in medical record databases. Patientsdo not return to tell the GP that disease is cured. For rare diseases,
the impact of different episode durations may be ignored both for
incidence and prevalence estimations. For chronic diseases, varying
the run‐in impacts the incidence with negligible impact on the
prevalence. We recommend that studies investigating chronic dis-
eases apply the longest possible run‐in to avoid misclassifying
prevalent cases as incident. We admit that this may lead to a
reduced sample size and depending on the database can potentially
limit the generalizability of the results.
Regarding AOM, there was no difference in incidence when we
compared 2 clinically plausible episode durations: 14 versus
30 days; 30 days has been applied in a previous study.7 Based on
the natural history of AOM, the actual duration of an episode is
not clear.26 Therefore, we also compared the incidence rates
(results not presented) we derived from the shortest (0 days) ver-
sus longest (90 days) assumptions; the estimates were significantly
different. When we performed the same comparisons for APN, the
result was not significant, further confirming that the episode dura-
tion is important for estimating the occurrence of only the common
outcomes. We observed that assuming episode duration of 30 vs
14 days significantly impacted the prevalence of AOM. The peak
in PR that was observed among children aged 9 to 10 years is
probably due to the comparatively lower number of events in that
age group. To derive the most clinically meaningful estimate of
incidence and/or prevalence of AOM and to a less extent APN,
perhaps the most plausible assumption for the duration of an
episode remains 30 days. It is highly unlikely that an episode will
last for as short as a few hours to 1 day or as long as 90 days.
We recommend further research to know the most appropriate
assumptions to apply when estimating the occurrence of AOM
and other common and recurrent childhood diseases. Prevalence
might be a good measure.
FIGURE 3 Incidence rate, incidence rate ratio, point prevalence and prevalence ratio for the transient outcomes [Colour figure can be viewed at
wileyonlinelibrary.com]
6 OSOKOGU ET AL.Still regarding AOM, the IRR seemed consistent across all ages,
but the absolute difference in IR estimates between the assumed
disease durations would be much smaller for older compared with
younger children. In older children, there is minimal or no differ-
ence in incidence estimates regardless of the assumed duration of
an episode.
Regarding both asthma and DM, increasing the run‐in period
considerably decreased the incidence. This finding is important
given that people can be observed for only a part of their lifetime;
despite conducting the current study over a 12‐year calendar
period, the median duration of follow‐up for the studied population
was 1500 days, showing the incomplete follow‐up (Figure 2).
Therefore, we recommend that the longest feasible run‐in period
be applied when estimating the incidence of chronic diseases. It
is expected that the point prevalence of chronic conditions should
increase with a longer run‐in period. However, the results for DM
did not reflect this. Rather, overall PR for DM, comparing
24 months' vs no run‐in was 0.82 (95% CI: 0.64; 1.04). This finding
may have resulted from the fact that type 1 DM is rare in children,
and therefore the estimates we derived for this condition are
unstable. Further research is required.
Although this is a methodological study that was primarily
aimed at testing assumptions rather than the incidence or preva-
lence estimates themselves, it is important to note that contrary
to what is expected, the prevalence of asthma did not increase
with increasing age. This finding may have resulted from thefollowing possible scenarios: first, older children may have seen
the physician less frequently; secondly, the case definition we
applied (based on previous studies) may have inadvertently
excluded newly diagnosed cases in older children because we
required at least 2 prescriptions for asthma medications in the year
following the initial diagnosis; thirdly, the fact that the study pop-
ulation was dynamic may have contributed to this finding. Perhaps,
conducting this study within a fixed cohort or using all the avail-
able look‐back information would have led to different results. Fur-
ther research is required.
This study has strengths and limitations. As strengths, we
tested assumptions that are plausible from both an epidemiological
and clinical point of view, and we demonstrated the ability to esti-
mate the impact of different assumptions. The limitations include
the following: first, we investigated only 4 different conditions
and tried to draw general conclusions. However, we believe the
conclusions hold but cannot provide thresholds when a disease or
condition is considered rare or common. This will be a continuum;
with the specific demonstrators, we tried to show that assumptions
should be considered and the impact may be considerable. Sec-
ondly, the case definitions for asthma and DM were aimed at
increasing the likelihood of identifying confirmed cases rather than
cases with a provisional diagnosis. This may have certain implica-
tions. Frequency measures may be underestimated for patients that
are lost to follow‐up in the year following the initial diagnosis or
those that were first diagnosed at 17 years but censored when
FIGURE 4 Incidence rate, incidence rate ratio, point prevalence, and prevalence ratio for the chronic outcomes [Colour figure can be viewed at
wileyonlinelibrary.com]
FIGURE 5 Summary of the impact of assumptions on the investigated outcomes [Colour figure can be viewed at wileyonlinelibrary.com]
OSOKOGU ET AL. 7they turn 18 years. Thirdly, there are conditions like depression
with insidious onset. For such conditions, more complex definitions
are required for identification of more relevant assumptions regard-
ing disease duration and run‐in. Fourthly, we applied the assump-
tions to only 1 database, a highly dynamic GPs' database. The
impact of the episode length is generalizable across all databases,
but the impact of the run‐in period may be less pronounced inmore stable regional or national databases where persons are
registered from birth. Lastly, the IPCI database is a GP database
and therefore may impact the identification of diseases or condi-
tions that are usually diagnosed by the specialist. However, the
database contains information on referrals and hospitalizations,
and therefore it is expected that the aforementioned impact will
be negligible.
8 OSOKOGU ET AL.5 | CONCLUSIONS
Population based EHR provide a rich and readily available source of data
for estimation of disease occurrence in children which can be used in PIPs.
Trial planning as well as potential market implications usually requires esti-
mates of occurrence in children. Assumptions on the episode length and
run in period may impact a lot on the absolute measures of occurrence
and should be explored, especially in more common childhood diseases.
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